Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess the Safety and Efficacy of MBM-01 for the Treatment of Ataxia Telangiectasia

NCT04887311 is registered in ClinicalTrials.gov with Matrix Biomed, Inc. as lead sponsor.

NCT NCT04887311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04887311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess the Safety and Efficacy of MBM-01 for the Treatment of Ataxia Telangiectasia
Lead sponsor
Matrix Biomed, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2021
Completion date
December 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ataxia telangiectasia, ataxia telangiectasia in children, ataxia telangiectasia louis-bar